1. Home
  2. SLVM vs DFTX Comparison

SLVM vs DFTX Comparison

Compare SLVM & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$38.90

Market Cap

1.9B

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$18.29

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SLVM
DFTX
Founded
1898
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SLVM
DFTX
Price
$38.90
$18.29
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$54.00
$40.25
AVG Volume (30 Days)
279.3K
1.4M
Earning Date
05-08-2026
05-04-2026
Dividend Yield
4.54%
N/A
EPS Growth
N/A
N/A
EPS
3.24
N/A
Revenue
$3,351,000,000.00
N/A
Revenue This Year
$0.98
N/A
Revenue Next Year
$2.28
N/A
P/E Ratio
$12.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.52
$14.62
52 Week High
$68.76
$19.62

Technical Indicators

Market Signals
Indicator
SLVM
DFTX
Relative Strength Index (RSI) 24.93 55.19
Support Level $38.06 $16.26
Resistance Level $46.59 $19.62
Average True Range (ATR) 1.58 0.94
MACD -0.48 -0.01
Stochastic Oscillator 1.62 55.05

Price Performance

Historical Comparison
SLVM
DFTX

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: